An international giant from pharmaceutical sector engaged in the manufacturing and marketing of active pharmaceutical ingredients which have a wide network in India and international markets. Cipla along with other pharma stocks have a bitter experience this year and fell about more than 6 % so far . It is beleived that high raw material cost due to inflation is one of the majour cause for this fall .Cipla is nearer to its 52 week low zone. Broken the support zone at 1000 levels and negative breakdown happened.Now it is tending towards its next support zone of 830 - 780 levels with weak momentum. Reducing debt and increasing profit gives an absolute hope against its sharp fall. Have a strong support at 800 levels and expecting a blocade at this level .
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.